ESMO 2024 Insights: TRIPLE-B Study - 1L Carboplatin-Cyclophosphamide vs. Paclitaxel +/- Atezolizumab for mTNBC

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

This video is featured in the 2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: TRIPLE-B Study - 1L Carboplatin-Cyclophosphamide vs. Paclitaxel +/- Atezolizumab for mTNBC

By 2024 ESMO Annual Meeting Insights Hub FEATURING Rosie Voorthuis

47 views

October 1, 2024

Comments 0

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Feat. J. O’Shaughnessy

Supporting Patients With Breast Cancer in the Clinic: Setting the Pa…

Feat. S. Dawood

2024 ESMO Annual Meeting Insights Hub: Breast Videos

New

ESMO 2024 Insights: Adjuvant Ribociclib + NSAI in HR+/HER2- eBC - 4-…

2024 ESMO Annual Meeting Insights Hub

P. Fasching

10 views

1 day ago

New

ESMO 2024 Insights: Residual Cancer Burden & Adjuvant Capecitabine i…

2024 ESMO Annual Meeting Insights Hub

S. Kim

20 views

5 days ago

New

ESMO 2024 Insights: TroFuse-010 Trial - Sacituzumab Tirumotecan ± Pe…

2024 ESMO Annual Meeting Insights Hub

S. Tolaney

215 views

2 weeks ago

View All

ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice

2024 ASCO® Annual Meeting Insights Hub

S. Tolaney, H. Rugo

4.1K views

5 months ago

ASCO® 2024 Breast Cancer Highlights: Top 5 Abstracts - DESTINY-Breas…

2024 ASCO® Annual Meeting Insights Hub

P. Tarantino

2.1K views

4 months ago

SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+ mBC?"

Insights from 2023 SABCS

S. Tolaney, H. Rugo

3.0K views

10 months ago

SABCS 2023 Insights: "CAPItello-291 Trial - Capivasertib & Fulvestra…

Integrity CE

A. Bardia

1.5K views

9 months ago

Year in Review: Breast Cancer

Dana-Farber Cancer Institute

P. Tarantino

2.4K views

9 months ago

ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-…

2024 ESMO Annual Meeting Insights Hub

P. Tarantino

721 views

1 month ago

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

1.9K views

7 months ago

Neoadjuvant Chemo for HR+ BC: Year in Review

Total Health

C. Ma

975 views

8 months ago

Metastatic Breast Cancer Comprehensive Review: ESMO Breast 2024 Awar…

Insights from ESMO Breast 2024 Annual Meeting

H. Rugo

1.2K views

5 months ago

SABCS 2023 Insights: "Biology or Stage? Tailoring Treatment for Prem…

Insights from 2023 SABCS

K. Kalinsky

1.8K views

11 months ago

ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNOTE-75…

Insights from 2023 ESMO Annual Meeting

P. Tarantino

2.1K views

1 year ago

ASCO® 2024 Expert Recap: "Metastatic Breast Cancer Deep Dive & Clini…

2024 ASCO® Annual Meeting Insights Hub

S. Tolaney, H. Rugo

919 views

4 months ago

What's New in Breast Cancer?

Dana-Farber Cancer Institute

S. Tolaney

1.5K views

10 months ago

ASCO® 2024 Noteworthy Abstracts in Breast Cancer

Sara Tolaney

H. Rugo

930 views

5 months ago

ESMO Breast 2024 Panel Discussion: "Key Updates in Breast Cancer"

Insights from ESMO Breast 2024 Annual Meeting

S. Tolaney, H. Rugo

909 views

5 months ago

ESMO 2024 Summary: eBC Panel Discussion on Key Studies - KEYNOTE-522…

2024 ESMO Annual Meeting Insights Hub

S. Tolaney, H. Rugo

514 views

1 month ago

Anthracyclines for Early Stage Breast Cancer - Do They Still Have a …

Scripps Health

V. Borges

1.3K views

8 months ago

ESMO 2024 Summary: Breast Cancer Highlights - KEYNOTE-522, NATALEE, …

2024 ESMO Annual Meeting Insights Hub

V. Kaklamani

478 views

1 month ago

ESMO Breast 2024 Summary: "Community Oncologists Highlights"

Insights from ESMO Breast 2024 Annual Meeting

S. Tolaney, H. Rugo

1.1K views

5 months ago

ESMO 2024 Summary: mBC Panel Discussion on Key Studies - DESTINY-Bre…

2024 ESMO Annual Meeting Insights Hub

S. Tolaney, H. Rugo

517 views

1 month ago

AUTOPLAY

Login

Login

Join VuMedi

ESMO 2024 Insights: TRIPLE-B Study - 1L Carboplatin-Cyclophosphamide vs. Paclitaxel +/- Atezolizumab for mTNBC

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Supporting Patients With Breast Cancer in the Clinic: Setting the Pa…

2024 ESMO Annual Meeting Insights Hub: Breast Videos

ESMO 2024 Insights: Adjuvant Ribociclib + NSAI in HR+/HER2- eBC - 4-…

ESMO 2024 Insights: Residual Cancer Burden & Adjuvant Capecitabine i…

ESMO 2024 Insights: TroFuse-010 Trial - Sacituzumab Tirumotecan ± Pe…

Recommended

ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice

ASCO® 2024 Breast Cancer Highlights: Top 5 Abstracts - DESTINY-Breas…

SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+ mBC?"

SABCS 2023 Insights: "CAPItello-291 Trial - Capivasertib & Fulvestra…

Year in Review: Breast Cancer

ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-…

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Neoadjuvant Chemo for HR+ BC: Year in Review

Metastatic Breast Cancer Comprehensive Review: ESMO Breast 2024 Awar…

SABCS 2023 Insights: "Biology or Stage? Tailoring Treatment for Prem…

ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNOTE-75…

ASCO® 2024 Expert Recap: "Metastatic Breast Cancer Deep Dive & Clini…

What's New in Breast Cancer?

ASCO® 2024 Noteworthy Abstracts in Breast Cancer

ESMO Breast 2024 Panel Discussion: "Key Updates in Breast Cancer"

ESMO 2024 Summary: eBC Panel Discussion on Key Studies - KEYNOTE-522…

Anthracyclines for Early Stage Breast Cancer - Do They Still Have a …

ESMO 2024 Summary: Breast Cancer Highlights - KEYNOTE-522, NATALEE, …

ESMO Breast 2024 Summary: "Community Oncologists Highlights"

ESMO 2024 Summary: mBC Panel Discussion on Key Studies - DESTINY-Bre…